Inventiva S.A. IVA
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -21.51%
- 1 year
- -12.05%
- Open
- 3.69
- Prev close
- 3.73
- Mkt cap
- 862.21M
- Vol
- 1.73M
- Avg vol
- 1.91M
- EPS
- -0.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.59
- High
- 3.76
- Forward P/E
- -5.34
- Beta
- 0.92
- Short ratio
- 3.38
- Inst. own
- 41.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Sep 25, 2026
- 50-d avg
- 4.53
- 200-d avg
- 5.07
- 1y target
- 14.62
2Y chart
Events in this range
- Mar 26, 2025Earnings: -2.19165; estimate -0.44; surprise -398.1%
- Sep 25, 2025Earnings: -1.8931; estimate -0.41; surprise -361.73%
- Nov 6, 2025Rating: Wolfe Research · — → Outperform
- Nov 18, 2025Rating: Guggenheim · Buy → Buy
- Jan 12, 2026Rating: Leerink Partners · — → Outperform
- Jan 28, 2026Rating: Barclays · — → Overweight
- Mar 19, 2026Rating: Truist Securities · — → Buy
- Mar 30, 2026Earnings: -1.07; estimate -0.23; surprise -365.22%
- Jul 17, 2026Rating: Cantor Fitzgerald · — → Overweight
- Sep 25, 2026Earnings: —; estimate -0.2; surprise —%
Signals (96)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 12, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 2, 2026 | 4 weeks ago |
| RSI: Oversold | Sep 29, 2026 | 1 month ago |
| RSI: Oversold | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 3, 2026 | 2 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
| SMA: Bearish | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 7, 2026 | 3 months ago |
| RSI: Oversold | Jun 26, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 25, 2026 | 4 months ago |
| RSI: Oversold | Jun 24, 2026 | 4 months ago |
| RSI: Oversold | Jun 15, 2026 | 4 months ago |
| RSI: Oversold | Jun 10, 2026 | 4 months ago |
| RSI: Oversold | Jun 5, 2026 | 4 months ago |
| RSI: Oversold | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | May 19, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 13, 2026 | 5 months ago |
| SMA: Bullish | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 28, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 15, 2026 | 6 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| MACD: Sell Signal | Feb 27, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 23, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 30, 2026 | 9 months ago |
| RSI: Overbought | Jan 13, 2026 | 9 months ago |
| SMA: Bullish | Dec 26, 2025 | 10 months ago |
| SMA: Bearish | Dec 17, 2025 | 10 months ago |
| SMA: Bullish | Dec 16, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 18, 2025 | 11 months ago |
| SMA: Bullish | Nov 14, 2025 | 11 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bearish | Nov 10, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 29, 2025 | 1 year ago |
| SMA: Bearish | Oct 28, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 23, 2025 | 1 year ago |
| SMA: Bullish | Oct 22, 2025 | 1 year ago |
| SMA: Bearish | Oct 16, 2025 | 1 year ago |
| SMA: Bullish | Oct 15, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 7, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 3, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 9, 2025 | 1 year ago |
| RSI: Overbought | Aug 27, 2025 | 1 year ago |
| RSI: Overbought | Aug 14, 2025 | 1 year ago |
| SMA: Bullish | Aug 6, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Aug 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 25, 2025 | 1 year ago |
| SMA: Bearish | Jul 21, 2025 | 1 year ago |
| SMA: Bullish | Jul 18, 2025 | 1 year ago |
| SMA: Bearish | Jul 15, 2025 | 1 year ago |
| SMA: Bullish | Jul 8, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 8, 2025 | 1 year ago |
| SMA: Bearish | Jun 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 16, 2025 | 1 year ago |
| SMA: Bullish | Jun 13, 2025 | 1 year ago |
| SMA: Bearish | Jun 12, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | May 27, 2025 | 1 year ago |
| SMA: Bearish | May 21, 2025 | 1 year ago |
| SMA: Bullish | May 20, 2025 | 1 year ago |
| SMA: Bearish | May 16, 2025 | 1 year ago |
| MACD: Sell Signal | May 1, 2025 | 1 year ago |
| RSI: Overbought | Apr 22, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 13, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 12, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 11, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 10, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 5, 2025 | 1 year ago |
| RSI: Overbought | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 12, 2025 | 1 year ago |
| SMA: Bearish | Feb 11, 2025 | 1 year ago |
| SMA: Bullish | Jan 30, 2025 | 1 year ago |
| SMA: Bearish | Jan 24, 2025 | 1 year ago |
| SMA: Bullish | Jan 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 7, 2025 | 1 year ago |
| RSI: Oversold | Dec 27, 2024 | 1 year ago |
| RSI: Oversold | Dec 23, 2024 | 1 year ago |
| RSI: Oversold | Dec 16, 2024 | 1 year ago |
Key statistics
- Market cap
- 1.05B
- Enterprise value
- 1.10B
- Trailing P/E
- 0.00
- Forward P/E
- -5.34
- PEG ratio
- 0.00
- Price / sales
- 155.48
- Price / book
- 0.00
- EPS (TTM)
- -2.21
- Beta
- 0.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 6.76M
- Revenue growth
- -89.90%
- Free cash flow
- -200.71M
- Total cash
- 99.84M
- Total debt
- 230.89M
- Return on equity
- 0.00%
- Shares outstanding
- 236.22M
- Short % of float
- 1.16%
- 50-day average
- 4.53
- 200-day average
- 5.07
Analyst view
Consensus: strong buy
- Target (low)
- 8.80
- Target (mean)
- 14.62
- Target (high)
- 26.00
- Strong buy1
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Sep 25, 2026
Expected Sep 25, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 25, 2026 | Jun 30, 2026 | -0.20 | — | — | — |
| Mar 30, 2026 | Dec 31, 2025 | -0.23 | -1.07 | -0.84 | -365.22% |
| Sep 25, 2025 | Jun 30, 2025 | -0.41 | -1.89 | -1.48 | -361.73% |
| Mar 26, 2025 | Dec 31, 2024 | -0.44 | -2.19 | -1.75 | -398.10% |
| Sep 25, 2024 | Jun 30, 2024 | -0.56 | -1.01 | -0.45 | -81.10% |
| Mar 27, 2024 | Dec 31, 2023 | -0.40 | -1.25 | -0.85 | -211.66% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 17, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Mar 19, 2026 | Truist Securities | init | — | Buy |
| Jan 28, 2026 | Barclays | init | — | Overweight |
| Jan 12, 2026 | Leerink Partners | init | — | Outperform |
| Nov 18, 2025 | Guggenheim | main | Buy | Buy |
| Nov 6, 2025 | Wolfe Research | init | — | Outperform |
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- inventivapharma.com
News
- Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout
- Inventiva (NASDAQ:IVA) Sets New 12-Month Low – Here’s What Happened
- 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
- Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
- Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
- Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s Why
- Truist Securities Maintains Buy on Inventiva, Raises Price Target to $18
- Inventiva (NASDAQ:IVA) Shares Gap Up – Here’s What Happened
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Your note
Sign in to keep a note on IVA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Caligan Partners, LP | 3.91% | 8,163,191 | 36.33M | Jun 29, 2026 |
| Samsara BioCapital, LLC | 3.02% | 6,314,805 | 28.10M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 1.91% | 4,000,000 | 17.80M | Jun 29, 2026 |
| Andera Partners | 1.74% | 3,633,181 | 16.17M | Jun 29, 2026 |
| Adar1 Capital Management, LLC | 1.73% | 3,606,656 | 16.05M | Jun 29, 2026 |
| Millennium Management Llc | 1.68% | 3,512,174 | 15.63M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| abrdn World Healthcare Fund | 0.58% | 1,214,281 | 5.40M | Jun 29, 2026 |
| abrdn Life Sciences Investors | 0.52% | 1,093,492 | 4.87M | Jun 29, 2026 |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 0.46% | 969,588 | 4.31M | Apr 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 0.33% | 685,400 | 3.05M | Jul 30, 2026 |
| iShares Trust-iShares MSCI EAFE Small-Cap ETF | 0.15% | 318,275 | 1.42M | Jun 29, 2026 |
| Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 0.15% | 313,483 | 1.39M | Jun 29, 2026 |